Pfizer (PFE) director James C. Smith reports 1,807 phantom stock units

Rhea-AI Filing Summary

Pfizer Inc. director reports additional deferred compensation in phantom stock units. On 12/31/2025, director James C. Smith acquired 1,807.229 phantom stock units tied to Pfizer common stock at a derivative security price of $24.9. After this transaction, he beneficially owned 166,119.84 derivative securities directly.

Each phantom stock unit represents one phantom share of Pfizer common stock. These units reflect deferred director compensation, including dividend equivalents, and will be settled in cash or common stock at the director’s election after he retires from the Board of Directors. The filing reports an acquisition of compensation-linked units rather than an open-market stock sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SMITH JAMES C

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock Units	(1)	12/31/2025		A		1,807.229		(2)	(2)	Common Stock	1,807.229	$24.9	166,119.84	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

	/s/ Shanice A. Reid, by power of atty., for James C. Smith	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pfizer (PFE) report for James C. Smith?

Pfizer director James C. Smith reported acquiring 1,807.229 phantom stock units tied to Pfizer common stock on 12/31/2025 as reflected in Table II.

How many derivative securities does the Pfizer (PFE) director own after this transaction?

Following the reported transaction, James C. Smith beneficially owned 166,119.84 derivative securities, held in direct ownership form.

What are the phantom stock units reported by Pfizer (PFE)?

Each unit represents one phantom share of common stock. These phantom stock units mirror the value of Pfizer shares but are used for deferred compensation rather than immediate share delivery.

How and when will the Pfizer (PFE) phantom stock units be settled?

The units represent deferred director's compensation, including dividend equivalents, and are settled in cash or common stock at the director’s election after his retirement from the Board of Directors.

Was this Pfizer (PFE) insider transaction a purchase on the open market?

No. The filing explains that the units represent deferred director's compensation compensation-related award rather than an open-market trade.

What was the reported price for the Pfizer (PFE) phantom stock units?

In Table II, the price of the derivative security is listed as $24.9 for the phantom stock units acquired on 12/31/2025.

What is James C. Smith’s relationship to Pfizer (PFE)?

The form identifies the reporting person’s relationship as a Director of Pfizer Inc., with the appropriate box checked under the relationship section.